Yokoe Takamichi, Fukada Ippei, Kobayashi Kokoro, Shibayama Tomoko, Miyagi Yumi, Yoshida Atsushi, Iwase Takuji, Ohno Shinji, Ito Yoshinori
Department of Breast Surgical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Case Rep Oncol. 2017 Jul 11;10(2):605-612. doi: 10.1159/000477897. eCollection 2017 May-Aug.
We present a case of a metastatic breast cancer patient with cystoid macular edema (CME) occurring during treatment with paclitaxel and bevacizumab. She had a history of neoadjuvant chemotherapy and partial mastectomy plus axillary lymph node dissection for stage IIB left-breast cancer. Twenty-four months later, she was diagnosed with multiple bone metastases and underwent chemotherapy with paclitaxel and bevacizumab. Thirty-three months after the initiation of the chemotherapy, she noticed bilateral blurred vision. The retinal thickening with macular edema was observed by optical coherence tomography, resulting in a diagnosis of CME. With cessation of paclitaxel and administrating ocular instillation of a nonsteroidal anti-inflammatory drug, her macular edema gradually reduced and disappeared in a month. While CME caused by chemotherapy is very rare, taxane may cause ocular adverse events such as CME. It is important to urge patients to consult an ophthalmologist promptly when they have visual complaints during taxane chemotherapy.
我们报告一例转移性乳腺癌患者，在接受紫杉醇和贝伐单抗治疗期间发生了囊样黄斑水肿（CME）。她有新辅助化疗史，曾因IIB期左乳腺癌接受保乳手术加腋窝淋巴结清扫术。24个月后，她被诊断为多发骨转移，并接受了紫杉醇和贝伐单抗化疗。化疗开始33个月后，她注意到双侧视力模糊。光学相干断层扫描观察到视网膜增厚伴黄斑水肿，诊断为CME。随着紫杉醇停用并给予非甾体抗炎药滴眼，她的黄斑水肿在1个月内逐渐减轻并消失。虽然化疗引起的CME非常罕见，但紫杉烷可能会引起如CME等眼部不良事件。在紫杉烷化疗期间，当患者出现视觉症状时，督促他们及时咨询眼科医生很重要。
